Risperdal Lawsuit News: New Order Issued In Pennsylvania Risperdal Litigation, Bernstein Liebhard LLP Reports

Share Article

The Firm is representing numerous Risperdal plaintiffs who have filed claims in Pennsylvania that allege the atypical antipsychotic medication caused the development of gynecomastia, or male breast growth.

Free Case Review
Our Firm has filed numerous Risperdal lawsuits in this litigation, and we continue to hear from individuals who allegedly experienced male breast growth due to its use. We will continue to closely monitor its progress.

Hundreds of Risperdal lawsuits (http://www.risperdallawsuit2014.com/) filed on behalf of individuals who allegedly developed gynecomastia (male breast growth) and other serious complications due to its use continue to move forward in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to an Order dated November 5, 2014, the parties have agreed and stipulated to the addition of Patriot Pharmaceuticals LLC to the case. Patriot Pharmaceuticals is a wholly-owned subsidiary of Johnson & Johnson’s Janssen Pharmaceuticals unit. (In Re: Risperdal Litigation, Case Number 100300296).

“Our Firm has filed numerous Risperdal lawsuits in this litigation, and we continue to hear from individuals who allegedly experienced male breast growth due to its use. We will continue to closely monitor its progress,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.

Risperdal Litigation
Court records indicate that more than 900 Risperdal lawsuits have been filed in Pennsylvania on behalf of patients who were allegedly harmed by the medication. In particular, the cases involving Risperdal and gynecomastia allege that the drug can cause the body to produce excess amounts of prolactin, a hormone tied to female breast growth and lactation. In men and boys, abnormally high levels of prolactin can lead to pain and swelling in the breasts, nipple discharge, and excessive growth of breast tissue which may require surgical removal to correct. The complaints accuse Johnson & Johnson and Janssen Pharmaceuticals, the manufacturers of Risperdal, of concealing these risks from the public. Plaintiffs also charge that the companies improperly marketed Risperdal for unapproved uses, including certain pediatric indications that were not approved by the U.S. Food & Drug Administration until 2006.

In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle charges with the U.S. Department of Justice involving the marketing of Risperdal and other medications. Among other things, federal prosecutors had alleged that Risperdal was improperly marketed for use in children, and accused the companies of concealing its serious side effects. As part of the settlement, Johnson & Johnson and Janssen pled guilty to a single criminal misdemeanor charge of misbranding the medication as a treatment for elderly dementia patients. However, the companies did not admit wrongdoing in resolving the charges pertaining to the marketing of Risperdal for children. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Risperdal patients who allegedly experienced male breast growth due to its use may be entitled to take legal action against the drug’s manufacturers. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website